Granted Patent
B2
US 12,290,507 · App. 17/501,701 · Granted May 6, 2025
Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
Assignee:
Aurigene Oncology Limited
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides methods for treating a cancer in a subject and for inhibiting tumor growth, metastasis or a dihydrorotate oxygenase enzyme activity of a tumor or cancer cell. At least one trisubstituted benzotriazole derivative with the formula (I) is administered to the subject or is contacted with the cancer cell. Compounds of formula (I) have substituents R 1 , R 2 and R 3 which have the meanings given in the specification, and pharmaceutically acceptable salts thereof.
Claims (5)
1. A method of treating a cancer selected from chronic lymphocytic leukemia, Hodgkin's disease, and follicular lymphoma, in a subject, comprising administering to the subject a therapeutically effective amount of compound 1 represented by the following structural formula:
or a pharmaceutically acceptable salt thereof.
2. The method according to claim 1 , wherein the cancer is chronic lymphocytic leukemia.
3. The method according to claim 1 , wherein the cancer is Hodgkin's disease.
4. The method according to claim 1 , wherein the cancer is follicular lymphoma.
Assignments (2)
CHANGE OF NAME
Recorded Jan 8, 2025
From: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
To: AURIGENE ONCOLOGY LIMITED
Reel/Frame 069848/0088 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 3, 2022
From: NELLORE, KAVITHA; HOSAHALLI, SUBRAMANYA
To: AURIGENE DISCOVERY TECHNOLOGIES LIMITED
Reel/Frame 059926/0986 →
Continuity (4)
Continuation
16607609
References Cited (131)
US 6841561B1
· Tan et al.
· 2005
[cited by applicant]
US 9630932B2
· Thunuguntla et al.
· 2017
[cited by applicant]
US 9937155B2
· Hosahalli
· 2018
[cited by applicant]
US 20130035329A1
· Saunders et al.
· 2013
[cited by applicant]
US 20130109643A1
· Riggins et al.
· 2013
[cited by applicant]
US 20180369206A1
· Nellore et al.
· 2018
[cited by applicant]
US 20190025313A1
· Si et al.
· 2019
[cited by applicant]
US 20190105304A1
· Thunuguntla et al.
· 2019
[cited by applicant]
US 20210088520A1
· Si et al.
· 2021
[cited by applicant]
US 20230285364A1
· Coco et al.
· 2023
[cited by applicant]
US 20230285365A1
· Coco et al.
· 2023
[cited by applicant]
CN 102348689A
· 2012
[cited by applicant]
CN 103476770A
· 2013
[cited by applicant]
CN 103965133A
· 2014
[cited by applicant]
EP 3019482B1
· 2018
[cited by applicant]
EP 3397625A1
· 2018
[cited by applicant]
JP 2004536122A
· 2004
[cited by applicant]
JP 2007015952A
· 2007
[cited by applicant]
JP 2012520251A
· 2012
[cited by applicant]
JP 2012520252A
· 2012
[cited by applicant]
JP 2013513613A
· 2013
[cited by applicant]
JP 2020517654A
· 2020
[cited by applicant]
RU 2374256C2
· 2009
[cited by applicant]
TW I372758B
· 2012
[cited by applicant]
TW 201902880A
· 2019
[cited by applicant]
WO 199635419A1
· 1996
[cited by applicant]
WO 200124785A2
· 2001
[cited by applicant]
WO 2003006425A2
· 2003
[cited by applicant]
WO 2006024034A1
· 2006
[cited by applicant]
WO 2008028860A1
· 2008
[cited by applicant]
WO 2010081898A1
· 2010
[cited by applicant]
WO 2010102825A1
· 2010
[cited by applicant]
WO 2010115736A2
· 2010
[cited by applicant]
WO 2011072174A1
· 2011
[cited by applicant]
WO 2013049112A1
· 2013
[cited by applicant]
WO 2014128669A2
· 2014
[cited by applicant]
WO 2015130728A1
· 2015
[cited by applicant]
WO 2015169944A1
· 2015
[cited by applicant]
WO 2017037022A1
· 2017
[cited by applicant]
WO 2017117372A1
· 2017
[cited by applicant]
WO 2018077923A1
· 2018
[cited by applicant]
WO 2018136009A1
· 2018
[cited by applicant]
WO 2018197997A1
· 2018
[cited by applicant]
WO 2019012030A1
· 2019
[cited by applicant]
WO 2019164794A1
· 2019
[cited by applicant]
WO 2020067412A1
· 2020
[cited by applicant]
WO 2020109625A1
· 2020
[cited by applicant]
WO 2020132471A1
· 2020
[cited by applicant]
WO 2021062157A1
· 2021
[cited by applicant]
WO 2021262874A1
· 2021
[cited by applicant]
WO 2022047051A1
· 2022
[cited by applicant]
Lolli et al., Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy. Recent Pat Anticancer Drug Discov. 2018;13(1):86-105.
[cited by applicant]
Anderson et al., Latest Medicinal Chemistry vol. 2, Technomic Co., Ltd., Japan. Sep. 25, 1999, pp. 347-365.
[cited by applicant]
Bastin et al., Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities. Org Proc Res Dev. 2000;4(5):427-435.
[cited by applicant]
Caira, Crystalline Polymorphism of Organic Compounds. Topics in Curren Chemistry, Design of Organic Solids. 1998;198:163-208.
[cited by applicant]
Morissette et al., High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv Drug Deliv Rev. Feb. 23, 2004;56(3):275-300.
[cited by applicant]
Serajuddin et al., Salt formation to improve drug solubility. Adv Drug Deliv Rev. Jul. 30, 2007;59(7):603-16.
[cited by applicant]
Schenkein, Agios at J.P. Morgan Healthcare Conference. Slideshow, 34 pages, Jan. 8, 2018.
[cited by applicant]
Akbay et al., D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. Mar. 1, 2014;28(5):479-90.
[cited by applicant]
Al-Soud et al., Synthesis and properties of new substituted 1,2,4-triazoles: potential antitumor agents. Bioorg Med Chem. Apr. 17, 2003;11(8):1701-8.
[cited by applicant]
Arnould et al., Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition. Oncotarget. Jul. 12, 2017;8(56):95206-95222.
[cited by applicant]
Batt, Inhibitors of dihydroorotate dehydrogenase. Expert Opinion on Therapeutic Patents. 1999;9(1):41-54.
[cited by applicant]
Baumann et al., Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther. Feb. 2009;8(2):366-75.
[cited by applicant]
Borodovsky et al., 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget. Oct. 2013;4(10):1737-47.
[cited by applicant]
Brown et al., Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. Apr. 2017;7(4):391-399.
[cited by applicant]
Cao et al., Targeting of Hematologic Malignancies with PTC299, a Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties. Mol Cancer Ther. Jan. 2019;18(1):3-16.
[cited by applicant]
Castelli et al., New Developments of Differentiation Therapy of Acute Myeloid Leukemia. Current Pharmacogenomics and Personalized Medicine. 2016;14(2):86-105.
[cited by applicant]
Chandrashakara, The treatment strategies of autoimmune disease may need a different approach from conventional protocol: a review. Indian J Pharmacol. Nov.-Dec. 2012;44(6):665-71.
[cited by applicant]
Chaturvedi et al., Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood. Oct. 17, 2013;122(16):2877-87.
[cited by applicant]
Chemistry Explained, Isomerism. Retrieved online at: http://www.chemistryexplained.com/Hy-Kr/Isomerism.html. 4 pages, (2016).
[cited by applicant]
Christian et al., The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. Oct. 2019;33(10):2403-2415.
[cited by applicant]
Dang et al., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. Dec. 10, 2009;462(7274):739-44.
[cited by applicant]
Dexter et al., Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2′-fluoro-1,1′-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors. Cancer Res. Nov. 1985;…
[cited by applicant]
Elsayed et al., Prognostic value of IDH1 mutations identified with PCR-RFLP assay in acute myeloid leukemia patients. J Egypt Natl Canc Inst. Mar. 2014;26(1):43-9.
[cited by applicant]
Emadi et al., Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematol. May 2015;90(5):E77-9.
[cited by applicant]
Golub et al., Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. Oct. 15, 1999;286(5439):531-7.
[cited by applicant]
Jin et al., Cancer-associated IDH1 and IDH2 mutations: therapeutic opportunities. EJC Supplement. Nov. 17, 2010;8(7):56. Poster 160.
[cited by applicant]
Kinnaird et al., Metabolic modulation of cancer: a new frontier with great translational potential. J Mol Med (Berl). Feb. 2015;93(2):127-42.
[cited by applicant]
Koundinya et al., Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers. Cell Chem Biol. Jun. 21, 2018;25(6):705-717.
[cited by applicant]
Ladds et al., A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nat Commun. Mar. 16, 2018;9(1):1107.
[cited by applicant]
Li et al., The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro. J Neuroimmunol. Dec. 15, 2013;265(1-2):82-90.
[cited by applicant]
Liu et al., Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents. Structure. Jan. 15, 2000;8(1):25-33.
[cited by applicant]
Luengo et al., Targeting Metabolism for Cancer Therapy. Cell Chem Biol. Sep. 21, 2017;24(9):1161-1180.
[cited by applicant]
Madak et al., Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. Pharmacol Ther. Mar. 2019;195:111-131. Pre-publication edition.
[cited by applicant]
Mathur et al., PTEN Regulates Glutamine Flux to Pyrimidine Synthesis and Sensitivity to Dihydroorotate Dehydrogenase Inhibition. Cancer Discov. Apr. 2017;7(4):380-390.
[cited by applicant]
Matsuda et al., Distinct global DNA methylation status in B-cell lymphomas: immunohistochemical study of 5-methylcytosine and 5-hydroxymethylcytosine. J Clin Exp Hematop. 2014;54(1):67-73.
[cited by applicant]
McDonald et al., Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase. Mol Cancer Ther. 2020;19:2502-15.
[cited by applicant]
McLean et al., Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase. Biochemistry. Feb. 20, 2001;40(7):2194-200.
[cited by applicant]
Munier-Lehmann et al., On dihydroorotate dehydrogenases and their inhibitors and uses. J Med Chem. Apr. 25, 2013;56(8):3148-67.
[cited by applicant]
NIH—National Cancer Institute, Targeted Cancer Therapies. Retrieved online at: http://www.cancer.gov/aboutcancer/treatment/types/targetedtherapies/targetedtherapiesfactsheet. 6 pages, Apr. 25, 2014.
[cited by applicant]
Ravandi et al., Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin. Cancer. May 15, 2012;118(10):2665-73.
[cited by applicant]
Ringshausen et al., The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia. Mar. 2008;22(3):635-8.
[cited by applicant]
Rohle et al., An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. May 3, 2013;340(6132):626-30.
[cited by applicant]
Ruckemann et al., Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem. Aug. 21, 1998;273(34):21682-91.
[cited by applicant]
Sykes et al., Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell. Sep. 22, 2016;167(1):171-186.e1-e8.
[cited by applicant]
Turcan et al., Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. Oct. 2013;4(10):1729-36.
[cited by applicant]
Ullrich et al., Recombinant expression of N-terminal truncated mutants of the membrane bound mouse, rat and human flavoenzyme dihydroorotate dehydrogenase. A versatile tool to rate inhibitor effects? Eur J Biochem. Mar.…
[cited by applicant]
Vyas et al., Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Mini Rev Med Chem. Oct. 2011;11(12):1039-55.
[cited by applicant]
Walse et al., The structures of human dihydroorotate dehydrogenase with and without inhibitor reveal conformational flexibility in the inhibitor and substrate binding sites. Biochemistry. Aug. 26, 2008;47(34):8929-36.
[cited by applicant]
Wang et al., Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. May 3, 2013;340(6132):622-6.
[cited by applicant]
Woo et al., The antilymphocytic activity of brequinar sodium and its potentiation by cytidine. Effects on lymphocyte proliferation and cytokine production. Transplantation. Aug. 1993;56(2):374-81.
[cited by applicant]
Yamaguchi et al., IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. Blood. 2013;122(21):4977.
[cited by applicant]
Zeng et al., Targeting dihydroorotate dehydrogenase in acute myeloid leukemia. Haematologica. Sep. 2018;103(9):1415-1417.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/IB2018/052710, dated Jul. 16, 2018, 8 pages.
[cited by applicant]
Dunleavy, Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL. Curr Treat Options in Oncol. 2015;16:58, 11 pages.
[cited by applicant]
Sun et al., Targeting the pyrimidine synthesis pathway for differentiation therapy of acute myelogenous leukemia. Translational Cancer Research. Feb. 28, 2017;6:S109-S111.
[cited by applicant]
Damia, Targeting DNA-PK in cancer. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 2020;821;111692, 7 pages.
[cited by applicant]
U.S. Appl. No. 14/784,708, filed Oct. 15, 2015, U.S. Pat. No. 9,630,932.
[cited by applicant]
U.S. Appl. No. 15/494,820, filed Apr. 24, 2017, U.S. Pat. No. 9,937,155.
[cited by applicant]
U.S. Appl. No. 15/718,961, filed Sep. 28, 2017, U.S. Pat. No. 10,080,740.
[cited by applicant]
U.S. Appl. No. 15/899,707, filed Feb. 20, 2018, 2018-0369206.
[cited by applicant]
U.S. Appl. No. 16/124,578, filed Sep. 7, 2018, 2019-0105304.
[cited by applicant]
U.S. Appl. No. 16/066,984, filed Jun. 28, 2018, 2019-0025313.
[cited by applicant]
U.S. Appl. No. 17/009,126, filed Sep. 1, 2020, 2021-0088520.
[cited by applicant]
U.S. Appl. No. 16/971,199, filed Aug. 19, 2020, 2021-0113531.
[cited by applicant]
U.S. Appl. No. 17/416,910, filed Jun. 21, 2021, 2022-0055995.
[cited by applicant]
U.S. Appl. No. 16/607,609, filed Oct. 23, 2019, U.S. Pat. No. 11,147,801.
[cited by applicant]